Breast Cancer

Recent advances in research are leading to new approaches for the diagnosis and clinical management of patients with breast cancer. ASCP is dedicated to helping ensure you stay abreast of the latest clinical practice recommendations and best practices to ensure optimal diagnosis, testing, and treatment for patients with breast cancer.

Educational Activities
Educational Activities

Online Modules on HER2-positive and HER2-low Breast Cancer

Pathologists, laboratory professionals, and other members of the cancer care team need to ensure that they are applying the latest clinical practice recommendations to ensure optimal HER2 testing processes. They also need a deeper understanding of current and emerging treatment options for patients with HER2-positive breast cancer. Furthermore, advances in the science of HER2-low breast cancer may lead to new diagnostic and treatment paradigms. The modules on this page will help pathologists, laboratory professionals, and other members of the cancer care team apply the latest clinical evidence to provide high-quality care for their patients.

Latest Courses

Ki67 as a Prognostic and Predictive Biomarker in HR-Positive/HER2-Negative Early Breast Cancer

Originally Broadcast January 20, 2022

This 60-minute interactive webinar will feature the expertise of a pathologist and an oncologist highlighting important and practice-changing developments related to the use of Ki67 biomarker testing in patients with HR-positive/HER2-negative early breast cancer, such as new clinical data with immediate implications for patient care. Case-based, and with expert perspectives and recommendations, this webinar addresses key educational gaps and controversies related to optimal Ki67 biomarker testing methods, including challenges with standardization, interpreting findings, and potential therapeutic implications for patients with HR-positive/HER2-negative early breast cancer to optimize clinical outcomes.

Register for Online Course

This activity is supported by an educational grant from Lilly.

 

Virtual Tumor Board #2: HER2 Testing in Breast Cancer: Improving IHC Performance

Originally Broadcast February 10, 2022

This virtual tumor board from ASCP will help you understand the latest evidence regarding HER2-low breast cancer, HER2 testing guidelines, the implications for the pathology team as HER2-low therapies emerge, and ways to streamline communications with oncologists and other members of the cancer care team.

Register for Online Course View on YouTube

Provided by the American Society for Clinical Pathology in partnership with Q-Synthesis, LLC and Clinical Care Options, LLC.

Funded by independent educational grants from AstraZeneca Pharmaceuticals and Daiichi Sankyo, Inc.

 

Virtual Tumor Board #1: The Science of HER2-low Breast Cancer and Implications for the Pathology Team

Originally Broadcast January 25, 2022

This virtual tumor board from ASCP will help you understand the science and emerging evidence around HER2-low breast cancer, as well as changes to practice that will be necessary in preparation for anticipated approvals of HER2-low breast cancer therapies.

Register for Online Course View on YouTube

Provided by the American Society for Clinical Pathology in partnership with Q-Synthesis, LLC and Clinical Care Options, LLC.

Funded by independent educational grants from AstraZeneca Pharmaceuticals and Daiichi Sankyo, Inc.

Additional Courses

HER2 In Breast Cancer: Testing Guidelines and New Treatment Approaches

Recorded October 2020

This CME/CMLE-accredited online module is designed to help Pathologists, laboratory professionals, and other members of the cancer care team apply the latest scientific evidence when evaluating HER2 status and be comfortable having an open dialogue surrounding challenging HER2 cases and how treatment is informed by HER2 status. Faculty also present information about how the emerging science around HER2‐low may impact patient care.

The activity offers 1.0 CME/CMLE credit.

Register Now View on YouTube

Supported by an independent educational grant from Daiichi Sankyo, Inc.

 

Updates in HER2 Testing in Breast Cancer

Released April 2020

This one-hour interactive, online CME/CMLE module is designed to help pathologists and laboratory professionals review and apply key concepts from the ASCO/CAP 2018 focused update on HER2 testing. The module will include a review of the ASCO/CAP 2018 focused update in HER2 testing in breast cancer, as well as application of the updates through case-based scenarios.

Register Now View on YouTube

Supported by an independent educational grant from Daiichi Sankyo, Inc.

 

Advances in HER2-positive and HER2-low Breast Cancer 

Released April 2020

This one-hour interactive, online CME/CMLE module is designed to help pathologists and laboratory professionals gain a deeper scientific understanding of recent advances in the diagnosis and management of HER2-positive and HER2-low breast cancer.

Register Now View on YouTube

Supported by an independent educational grant from Daiichi Sankyo, Inc.

Ki67 Testing in Breast Cancer Twitter Chat

ASCP is hosting a CME/CMLE-accredited Twitter chat to allow you to engage with breast cancer experts in pathology and oncology to further advance your knowledge of how to optimally assess patients with HR-positive/HER2-negative early breast cancer for Ki67 and accurately report, interpret, and apply results of the testing to optimal therapy selection.

The Twitter chat covers topics presented in ASCP’s online module, as well as a recent Journal of Clinical Oncology article by David Hicks, MD, and Ruth M. O’Regan, MD, “Improving Outcomes for High-Risk Hormone Receptor-Positive Breast Cancer with CDK Inhibition.”

Provided by the American Society for Clinical Pathology in partnership with Clinical Care Options, LLC.

Funded by an independent educational grant from Lilly

How to Participate

Join ASCP for a Twitter chat about Ki67 testing in breast cancer.

When: May 19, from 8:00 p.m. to 9:00 p.m. Eastern

Credits: 1 CME/CMLE credit

Claim Credit

The Twitter chat will use the hashtag #Ki67 and be moderated by:

  • David Hicks, MD
    Professor and Director of IHC-ISH Laboratory and Breast Subspecialty Service
    Department of Pathology and Laboratory Medicine
    University of Rochester Medical Center
  • Ruth O’Regan, MD
    @oreganruth

    Professor, Chair, and Charles A. Dewey Professor
    Department of Medicine
    University of Rochester Medical Center

Ki67 Testing in Early Breast Cancer Podcast

Ki67 as a Prognostic and Predictive Biomarker in HR-Positive/HER2-Negative Early Breast Cancer Webinar

This podcast from ASCP will highlight important and practice-changing developments related to Ki67 testing, including the standardization, interpretation of findings, and potential therapeutic implications for patients with HR-positive/HER2-negative early breast cancer to optimize clinical outcomes.

Guest panelists:
Sunil S. Badve, MD, FRCPath
Manali Bhave, MD

Listen Now Claim Credit

Provided by the American Society for Clinical Pathology in partnership with Clinical Care Options, LLC.

This activity is supported by an educational grant from Lilly

Access all of ASCP’s Inside the Lab podcasts here.

HER2-low Breast Cancer Podcasts

The Science of HER2-low Breast Cancer and Implications for the Pathology Team

This podcast from ASCP will help you understand the science and emerging evidence around HER2-low breast cancer, as well as changes to practice that will be necessary in preparation for anticipated approvals of HER2-low breast cancer therapies.

Guest panelists:
Ali Brown, MD, FASCP
Erinn Downs-Kelly, DO
Aysegul A. Sahin, MD

Listen Now Claim Credit

Provided by the American Society for Clinical Pathology in partnership with Q-Synthesis, LLC and Clinical Care Options, LLC.

Funded by independent educational grants from AstraZeneca Pharmaceuticals and Daiichi Sankyo, Inc.

HER2 Testing in Breast Cancer: Improving IHC Performance

This podcast from ASCP will help you understand current guidelines for scoring HER2 IHC and factors that may affect IHC performance, updated scoring for HER2 ISH, HER2 heterogeneity and HER2-low tumors, and practical applications of HER2 scoring and reporting challenges.

Guest panelists:
Ali Brown, MD, FASCP
Erinn Downs-Kelly, DO
Aysegul A. Sahin, MD

Listen Now Claim Credit

Provided by the American Society for Clinical Pathology in partnership with Q-Synthesis, LLC and Clinical Care Options, LLC.

Funded by independent educational grants from AstraZeneca Pharmaceuticals and Daiichi Sankyo, Inc.

Access all of ASCP’s Inside the Lab podcasts here.

Resources on Ki67 Testing

These resources, related to a January 2022 ASCP webinar on Ki67 testing, highlight important and practice-changing developments, highlight important and practice-changing developments, such as new clinical data with immediate implications for patient care. The resources address key educational gaps and controversies related to optimal testing methods, addressing challenges with standardization, interpreting findings, and potential therapeutic implications for patients with HR-positive/HER2-negative early breast cancer to optimize clinical outcomes.

Access Ki67 Slide Deck

Access Ki67 At-a-Glance Resource

Access Ki67 Expert Commentary

Provided by the American Society for Clinical Pathology in partnership with Clinical Care Options, LLC.

This activity is supported by an educational grant from Lilly

Downloadable Slide Deck: HER2-low Breast Cancer 

This downloadable, easily sharable set of slides is intended for pathologists to use to educate colleagues on HER2-low breast cancer. The slides cover the following topics:

  • The science of HER2-low breast cancer
  • Clinical practice guidelines for HER2 testing in patients with breast cancer
  • Emerging therapies designed to treat patients with HER2-low breast cancer

Download Here

Provided by the American Society for Clinical Pathology in partnership with Q-Synthesis, LLC and Clinical Care Options, LLC.

Funded by independent educational grants from AstraZeneca Pharmaceuticals and Daiichi Sankyo, Inc.

ASCP Pathology Trailblazers in HER2-low Breast Cancer

ASCP, working in collaboration with Q Synthesis LLC, invites pathologists to participate in a unique cohort-based leadership development CME program called Pathology Trailblazers: HER2-low Breast Cancer Collaborative Learning Exchange.

This program will begin in May 2022 and run for approximately 3 months. Details regarding the program commitments and requirements are below.

Participation Details:

  • Using case studies and facilitated discussion, program faculty will guide participants through a leadership framework that outlines how to prepare for the emerging category of HER2-low breast cancer.
  • Participants will commit to demonstrating personal leadership growth and development through this program.
  • ASCP will hold two (2) CME virtual meetings where participants will engage in group dialogue. Each meeting will be 60 minutes.
  • Participants can claim CME credits for completing the program.
  • ASCP will publicly recognize all who complete the Pathology Trailblazers program by listing their names on an ASCP website and promoting their achievements and commitments to improve patient care.

Applications Are Now Closed

Pathology Trailblazers: HER2-low Breast Cancer Collaborative Learning Exchange is designed to:

  • Strengthen leadership skills among pathologists
  • Increase knowledge and competence around the evolving landscape of HER2-low breast cancer
  • Improve how HER2 testing is performed, classified, and reported
  • Support the dissemination and implementation of best practices around HER2 testing and reporting in breast cancer

Provided by the American Society for Clinical Pathology in partnership with Q-Synthesis, LLC and Clinical Care Options, LLC.

Funded by independent educational grants from AstraZeneca Pharmaceuticals and Daiichi Sankyo, Inc.

Online Modules on HER2-low Breast Cancer

Virtual Tumor Board #1: The Science of HER2-low Breast Cancer and Implications for the Pathology Team

Originally Broadcast January 25, 2022

This virtual tumor board from ASCP will help you understand the science and emerging evidence around HER2-low breast cancer, as well as changes to practice that will be necessary in preparation for anticipated approvals of HER2-low breast cancer therapies.

Register for Online Course View on YouTube

Provided by the American Society for Clinical Pathology in partnership with Q-Synthesis, LLC and Clinical Care Options, LLC.

Funded by independent educational grants from AstraZeneca Pharmaceuticals and Daiichi Sankyo, Inc.

 

Virtual Tumor Board #2: HER2 Testing in Breast Cancer: Improving IHC Performance

Originally Broadcast February 10, 2022

This virtual tumor board from ASCP will help you understand the latest evidence regarding HER2-low breast cancer, HER2 testing guidelines, the implications for the pathology team as HER2-low therapies emerge, and ways to streamline communications with oncologists and other members of the cancer care team.

Register for Online Course View on YouTube

Provided by the American Society for Clinical Pathology in partnership with Q-Synthesis, LLC and Clinical Care Options, LLC.

Funded by independent educational grants from AstraZeneca Pharmaceuticals and Daiichi Sankyo, Inc.

Downloadable Slide Deck: HER2-low Breast Cancer 

This downloadable, easily sharable set of slides is intended for pathologists to use to educate colleagues on HER2-low breast cancer. The slides cover the following topics:

  • The science of HER2-low breast cancer
  • Clinical practice guidelines for HER2 testing in patients with breast cancer
  • Emerging therapies designed to treat patients with HER2-low breast cancer

Download Here

Provided by the American Society for Clinical Pathology in partnership with Q-Synthesis, LLC and Clinical Care Options, LLC.

Funded by independent educational grants from AstraZeneca Pharmaceuticals and Daiichi Sankyo, Inc.

HER2-low Breast Cancer Podcasts

The Science of HER2-low Breast Cancer and Implications for the Pathology Team

This podcast from ASCP will help you understand the science and emerging evidence around HER2-low breast cancer, as well as changes to practice that will be necessary in preparation for anticipated approvals of HER2-low breast cancer therapies.

Guest panelists:
Ali Brown, MD, FASCP
Erinn Downs-Kelly, DO
Aysegul A. Sahin, MD

Listen Now Claim Credit

Provided by the American Society for Clinical Pathology in partnership with Q-Synthesis, LLC and Clinical Care Options, LLC.

Funded by independent educational grants from AstraZeneca Pharmaceuticals and Daiichi Sankyo, Inc.

HER2 Testing in Breast Cancer: Improving IHC Performance

This podcast from ASCP will help you understand current guidelines for scoring HER2 IHC and factors that may affect IHC performance, updated scoring for HER2 ISH, HER2 heterogeneity and HER2-low tumors, and practical applications of HER2 scoring and reporting challenges.

Guest panelists:
Ali Brown, MD, FASCP
Erinn Downs-Kelly, DO
Aysegul A. Sahin, MD

Listen Now Claim Credit

Provided by the American Society for Clinical Pathology in partnership with Q-Synthesis, LLC and Clinical Care Options, LLC.

Funded by independent educational grants from AstraZeneca Pharmaceuticals and Daiichi Sankyo, Inc.

Access all of ASCP’s Inside the Lab podcasts here.